Louie Pasculli

The senior vice president for research at the Kessler Foundation discussed findings showing associations between reductions in neurofilament light chain and gains in cognitive processing speed, verbal memory, and visual memory in patients with early relapsing multiple sclerosis treated with ozanimod. [WATCH TIME: 3 minutes]

The professor of psychiatry and neurology reviewed approaches to treating chorea, cognitive impairment, apathy, irritability, and aggression in Huntington disease, while highlighting the promise of huntingtin-lowering therapies.

At ATMRD 2026, the director of the Parkinson's Disease and Movement Disorders Program at the Cleveland Clinic discussed the importance of movement phenomenology and accurate diagnosis in guiding treatment decisions for patients with hyperkinetic disorders. [WATCH TIME: 7 minutes]

The professor at MedStar Georgetown University Hospital spoke about a live session that featured patient evaluations and injection demonstrations designed to help clinicians refine treatment strategies for dystonia, spasticity, sialorrhea, and other neurologic conditions. [WATCH TIME: 2 minutes]

At ATMRD 2026, the director of Movement Disorders at Banner Sun Health Research Institute discussed emerging biomarker and imaging technologies, the importance of clinical diagnostic expertise, and the evolving treatment landscape for atypical parkinsonian disorders and adult-onset ataxias.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Brain insulin resistance!

At CMSC 2026, the neuroimmunologist and director at OhioHealth MS Center, discussed results from the phase 3 FENhance 1 and 2 studies, highlighting significant reductions in relapse rates and robust MRI outcomes. [WATCH TIME: 3 minutes]

As the MS community reflects on World MS Day, Alla Wilson, a clinical ambulatory pharmacist at Shields Health Solutions, discusses how integrated specialty pharmacy models can improve treatment access, adherence, and patient-reported outcomes for multiple sclerosis.

12-montn interim findings from an ongoing phase 1/2 study showed up to 69% reductions in mutant huntingtin protein and favorable cUHDRS trends with the investigational oral RNA-splicing modifier SKY-0515.

A clinical research coordinator at SunnyBrook Health Sciences Centre, explained key factors of the computerized cognitive training program that contributed to cognitive improvement. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is mmoldering inflammation in MS!

The director of the Stony Broke MS Comprehensive Care Center reviewed late-breaking subgroup data evaluating high-efficacy therapy in patients with highly active relapsing multiple sclerosis and discussed the evolving role of early intervention. [WATCH TIME: 5 minutes]

A literature review suggests ferritin may serve as a “dual-edged” biomarker in multiple sclerosis, with elevated levels associated with disease progression and low levels linked to impaired remyelination.

Preliminary phase 1a findings suggest the investigational tau aggregation inhibitor OLX-07010 demonstrated favorable safety and pharmacokinetic profiles in healthy volunteers, supporting continued development in Alzheimer disease.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is mitochondrial dysfunction in neurodegeneration!

Sara Cuccurullo, MD, chair, vice president, and medical director, Hackensack Meridian JFK Johnson Rehabilitation Institute discussed how structured cardiovascular rehabilitation may improve recovery outcomes, reduce mortality, and influence future Medicare coverage for poststroke care.

Sara Cuccurullo, MD, chair, vice president, and medical director, Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed emerging evidence supporting structured cardiovascular rehabilitation after stroke and ongoing efforts to expand access through potential Medicare policy changes.

The FDA's acceptance and priority review of levacetylleucine for ataxia-telangiectasia positions the therapy to potentially become the first approved treatment for the rare neurodegenerative disorder.

From exercise and lifestyle medicine to neuromodulation and vagus nerve stimulation, Andrew Abdou, DO, discusses emerging approaches that may help stroke patients continue recovery beyond traditional timelines.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is glymphatic system for Parkinson!

The professor of cognitive neuroscience and imaging at the University of Western Ontario, Canada, detailed new research using the Creyos platform and machine learning to develop a rapid, scalable cognitive screener designed to identify early signs of cognitive decline and dementia risk.

Experts shared their clinical perspectives and insights on main focus areas at the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois.

A prospective postapproval study showed that responsive neurostimulation with the RNS System was associated with sustained seizure reductions and a favorable interim safety profile over 3 years in adults with drug-resistant focal epilepsy.

A phase 2 trial found that the oral complement factor D inhibitor vemircopan did not demonstrate efficacy over placebo in adults with acetylcholine receptor antibody–positive generalized myasthenia gravis, leading to early termination of the study.

Kinan Muhammed, MD, PhD, consultant neurologist and co-founder and Chief Medical Officer for Kneu Health, discussed how smartphone-based remote monitoring tools may help clinicians track motor and cognitive changes in Parkinson disease and dementia more continuously.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Stroke Awareness Month!

BIOX-101 showed early signals of reduced edema growth and improved functional outcomes in a phase 2a intracerebral hemorrhage trial, with a favorable safety profile, supporting advancement into a planned adaptive phase 2b/3 study.

The FDA has expanded the use of efgartigimod alfa-fcab and Hytrulo to include adults with AChR-Ab seronegative generalized myasthenia gravis, marking the first approved FcRn-targeted therapy for this patient population.

Neurava secured a $4M NIH grant to develop and validate an AI-driven wearable platform for SUDEP risk prediction and real-time monitoring, aiming to improve clinical decision-making and early intervention in epilepsy care.

Clene plans to pursue accelerated FDA approval for CNM-Au8 in ALS based primarily on neurofilament light biomarker data and phase 2 studies, with a confirmatory phase 3 trial expected to follow.